Orphazyme A/S
CSE:ORPHA
Orphazyme A/S
CSE:ORPHA
Price:
850
DKK
1.19%
Market Closed
Market Cap:
kr34m
Balance Sheet
Balance Sheet Decomposition
Orphazyme A/S
Orphazyme A/S
Balance Sheet Decomposition is not available for
Orphazyme A/S
Orphazyme A/S
Balance Sheet
Orphazyme A/S
Orphazyme A/S
Currency: DKK
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
68
|
14
|
632
|
395
|
124
|
727
|
102
|
42
|
11
|
|
| Cash Equivalents |
68
|
14
|
632
|
395
|
124
|
727
|
102
|
42
|
11
|
|
| Total Receivables |
7
|
9
|
6
|
6
|
6
|
6
|
36
|
16
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
29
|
4
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
12
|
1
|
|
| Other Current Assets |
6
|
5
|
11
|
23
|
19
|
51
|
20
|
2
|
7
|
|
| Total Current Assets |
81
|
28
|
648
|
423
|
148
|
784
|
159
|
57
|
19
|
|
| PP&E Net |
1
|
1
|
2
|
2
|
18
|
20
|
8
|
0
|
0
|
|
| PP&E Gross |
1
|
1
|
2
|
2
|
18
|
20
|
8
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
2
|
2
|
3
|
4
|
5
|
6
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
10
|
11
|
11
|
12
|
2
|
0
|
0
|
|
| Note Receivable |
0
|
3
|
3
|
3
|
3
|
3
|
3
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
3
|
2
|
4
|
1
|
0
|
0
|
|
| Total Assets |
85
N/A
|
32
-62%
|
663
+1 975%
|
441
-33%
|
181
-59%
|
822
+355%
|
173
-79%
|
57
-67%
|
19
-66%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
2
|
5
|
40
|
42
|
32
|
72
|
58
|
9
|
5
|
|
| Accrued Liabilities |
0
|
0
|
6
|
9
|
16
|
50
|
29
|
1
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
13
|
37
|
34
|
0
|
0
|
|
| Other Current Liabilities |
8
|
10
|
1
|
2
|
5
|
7
|
9
|
5
|
0
|
|
| Total Current Liabilities |
11
|
14
|
47
|
53
|
66
|
167
|
129
|
16
|
5
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
61
|
34
|
6
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
2
|
28
|
0
|
0
|
|
| Total Liabilities |
11
N/A
|
14
+34%
|
47
+226%
|
53
+13%
|
128
+141%
|
202
+58%
|
164
-19%
|
16
-90%
|
5
-68%
|
|
| Equity | ||||||||||
| Common Stock |
3
|
3
|
20
|
20
|
20
|
35
|
35
|
35
|
12
|
|
| Retained Earnings |
154
|
212
|
328
|
556
|
891
|
1 497
|
2 109
|
2 081
|
2
|
|
| Additional Paid In Capital |
225
|
226
|
924
|
924
|
924
|
2 082
|
2 082
|
2 087
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Total Equity |
74
N/A
|
18
-76%
|
616
+3 416%
|
388
-37%
|
53
-86%
|
621
+1 071%
|
9
-98%
|
41
+339%
|
14
-65%
|
|
| Total Liabilities & Equity |
85
N/A
|
32
-62%
|
663
+1 975%
|
441
-33%
|
181
-59%
|
822
+355%
|
173
-79%
|
57
-67%
|
19
-66%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
20
|
20
|
20
|
20
|
20
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
